Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
SPA Scintillation beads are microspheres containing scintillant which emit light in the blue region of the visible spectrum. As a result, these beads are ideally suited to use with photomultiplier tube (PMT) counters such as the MicroBeta2 or TopCount.
Two types of core SPA Scintillation bead are available - yttrium silicate (YSi) and Polyvinyltoluene (PVT). PVT beads are plastic, larger in size, and stay in suspension longer than the crystalline YSi beads.
Scintillation proximity assay (SPA) is a homogeneous and versatile technology for the rapid and sensitive assay of a wide range of biological processes, including applications using enzyme and receptor targets, radioimmunoassays, and molecular interactions. When 3H, 14C, 33P, and 125I radioisotopes decay, they release β-particles (or Auger electrons, in the case of 125I). The distance these particles travel through an aqueous solution is dependent on the energy of the particle. If a radioactive molecule is held in close enough proximity to a SPA Scintillation Bead or a SPA Imaging Bead, the decay particles stimulate the scintillant within the bead to emit light, which is then detected in a PMT-based scintillation counter or on a CCD-based imager, respectively. However, if the radioactive molecule does not associate with the SPA bead, the decay particles will not have sufficient energy to reach the bead and no light will be emitted. This discrimination of binding by proximity means that no physical separation of bound and free radiochemical is required.
|Bead Type or Core Bead Type||YSi|
|Coating Treatment||RNA Binding|
|Product Brand Name||SPA Scintillation Beads|
|Unit Size||500 mg|
Interactions between proteins are a key feature of many biochemical processes, for example cell signalling. In the absence of any enzymatic activity, measurement of protein:protein interactions has presented problems. Scintillation Proximity Assay (SPA) technology permits the direct measurement of binding of one protein to another.
Many proteins are able to recognize and subsequently bind DNA. These proteins were first identified by their presence in isolated DNA complexes, by their ability to bind DNA in vitro, and by their absolute requirement in many DNA-dependent functions.
SH2 and SH3 domains are small, independent domains of about 100 or 70 amino acid residues respectively. They are foundin a variety of proteins, and can occur together or separately. SH2 domains are thought to be involved in signal transduction mechanisms. Some SH2 domains control enzyme activity by binding membrane-bound receptors to regulate downstream events such as kinase cascades.
A signal increase SPA assay to measure HCV RNA helicase activity has been developed using a duplex RNA substrate in which one of the strands was [ P] labelled. The assay was optimized in microtubes, then adapted for use in 96 and 384 well microplates, and in all formats a signal:noise ratio of 10:1 was achievable. The homogenous assay format makes it suitable for high throughput screening applications.
Assays to quantitate changes in DNA binding proteins can lead to earlier diagnosis of disease, while the development of drugs to counteract the loss of gene regulation is the likely future of biomedicine. The p53 tumor suppressor controls the cell cycle of normal cells. Mutations in this gene are associated with increased risk in developing metastatic disease, poorer prognosis and decreased sensitivity of cancer cells to chemotherapeutic agents.
NF-B is a transcription factor of potential therapeutic relevance due to its central role in regulating the transcription of a large number of genes involved in cellular defence. In this study we have investigated the interaction of the p65 sub unit to a dsDNA substrate containing the 10bp consensus DNA binding sequence to which it binds with high affinity.